AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship ...

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

You might receive some injections at a doctor’s office, or you may be able to inject the medication yourself at home. The dosing schedule varies for each medication. You can use biologics in ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.